Two abstracts will be presented at the 2018 International Symposium on Pediatric Neuro-Oncology (ISPNO), Denver, CO, June 30 – July 3. Additional information on the abstracts can be found below: DIPG-54: “Treatment of a pediatric patient with an H3.3 K27M mutant DIPG with ONC201, a selective DRD2 antagonist”. DIPG-42: “Can we change the landscape
Josh Allen, Senior Vice President of Research and Development at Oncoceutics will share his personal experience as a researcher and will discuss the potential of molecular medicine with respect to cancers like DIPG. Tomorrow’s episode and all previous episodes can be found here. More information about CCTalkRadio can be found here. TogiNet Radio 2.0 is
Lee Schalop, MD, COO of Oncoceutics to present ONC201 and our clinical trials in glioma patients with the H3 K27M mutation at the BioNJ BioPartnering Conference in Somerset, NJ on May 3, 2018. His presentation will further talk about relevant background information for H3 K27M-mutant brain tumors, including DIPG and other midline gliomas, and discuss
Josh Allen, PhD and SVP of Research and Development at Oncoceutics will be presenting ONC201 at 2018 Experimental Biology in San Diego, April 21 – 25. The presentation will discuss the role of DRD2 in oncology and speak about the ability of imipridones to target GPCRs with a high degree of selectivity. ONC201, the founding
Business Development